Evidence map›Paper›PMID 32266804›Full record

ArticleJournal of gynecologic oncology2020

National screening programs for cervical cancer in Asian countries.

Eiko Saitoh Aoki, Rutie Yin, Kemin Li, Neerja Bhatla, Seema Singhal, Dwiana Ocviyanti, Kumiko Saika, Mina Suh, Miseon Kim, Wichai Termrungruanglert

2 registry-linked trialsOpen access · diamondAbstract read
In one paragraph

Article in Journal of gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 49 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 6 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06261879 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood

TypeinterventionalSponsorWomenX Biotech LimitedRan2023 to 2025Enrolled300ConditionsCervical Cancer, CINArmsSpecial sanitary pad
NCT06261892 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine

TypeinterventionalSponsorWomenX Biotech LimitedRan2023 to 2025Enrolled300ConditionsCervical CancerArmsCollect HPV DNA from urine
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 6 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Prevalence of Cervical Cancer Screening in Asia: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025
    Pooled it
  5. Pooled it
  6. Disparities in Cervical Cancer Screening by Disability Types: a Systematic Review.Journal of cancer education : the official journal of the American Association for Cancer Education · 2023
    Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Associations Between Regional Factors and Cervical Cancer Screening Coverage in Tokyo.Asian Pacific journal of cancer prevention : APJCP · 2026
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 7 countries.

Eiko Saitoh AokiDepartment of Preventive Medicine Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5225-4673
Rutie YinDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-9221-6727
Kemin LiKey Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Beijing, China.ORCID https://orcid.org/0000-0001-8731-5846
Neerja BhatlaDepartment of Gynecology, All India Institute of medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0002-3894-2795
Seema SinghalDepartment of Gynecology, All India Institute of medical Sciences, New Delhi, India.ORCID https://orcid.org/0000-0002-8644-7684
Dwiana OcviyantiDepartment of Obstetrics and Gynecology, Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia.ORCID https://orcid.org/0000-0001-7068-0070
Kumiko SaikaDivision of Medical Support and Partnership, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.ORCID https://orcid.org/0000-0002-4164-4430
Mina SuhNational Cancer Control Institute, National Cancer Center, Goyang, Korea.ORCID https://orcid.org/0000-0001-8101-7493
Miseon KimDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea. miseonkim@chamc.co.kr.ORCID https://orcid.org/0000-0002-5118-9275
Wichai TermrungruanglertDepartment of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.ORCID https://orcid.org/0000-0003-3510-0047
All India Institute of Medical Sciences · INCHA University · KRChulalongkorn University · THMinistry of Education and Child Care · CAMita Hospital · JPNational Cancer Center · KRRumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo · IDSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is still one of the most common female cancers in Asia and the leading cause of cancer-related deaths in low- and middle-income countries. Nowadays, national screening programs for cervical cancer are widely provided in Asian countries. We reviewed the National Cancer Screening Program (NCSP) in China, India, Indonesia, Japan, Korea, and Thailand. The NCSP were established at varying times, from 1962 in Japan to 2014 in Indonesia. The primary screening method is based on cytology in all countries except for India and Indonesia. In India and Indonesia, visual inspection of the cervix with acetic acid (VIA) is mainly used as a primary screening method, and a "see and treat" strategy is applied to women with a positive VIA result. The starting age of NCSP ranges from 18 years in China to 30 years in Thailand. The screening interval is 2 years in all countries except for China and Indonesia, in which it is 3 years. Uptake rates of NCSP vary from 5.0%-59.7%. Many women in low- and middle-income countries still do not participate in NCSP. To improve uptake rates and thereby prevent more cases of cervical cancer, Asian countries should continue to promote NCSP to the public using various approaches.

Indexed as

Uterine Cervical NeoplasmsAdolescentAdultAgedChinaEarly Detection of CancerFemaleHumansIndiaJapanMiddle AgedRepublic of KoreaThailandYoung AdultAsiaCancer ScreeningCervical CancerNational Health Programs

Identifiers

PMID32266804
PMCPMC7189071
OpenAlexW3009549150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.